<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005949</url>
  </required_header>
  <id_info>
    <org_study_id>STOP Persistent AF PAS</org_study_id>
    <nct_id>NCT05005949</nct_id>
  </id_info>
  <brief_title>STOP Persistent AF PAS</brief_title>
  <official_title>STOP Persistent AF Post-Approval Study, a Sub-study to the Cryo Global Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter,&#xD;
      observational trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STOP Persistent AF Post Approval Study (PAS) is a sub-study to the Cryo Global Registry.&#xD;
      The PAS is a prospective, global, multicenter, observational trial. The purpose of the PAS is&#xD;
      to describe long-term clinical performance and safety data in the Persistent AF population&#xD;
      treated with Arctic Front™ and Freezor™ MAX Families of Cardiac Cryoablation Catheters&#xD;
      (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System). This PAS is a&#xD;
      condition of the Pre-Market Approval order (P100010/S098) by the U.S. Food and Drug&#xD;
      Administration. Up to 400 subjects will be enrolled to ensure 355 are treated. A minimum of&#xD;
      50% of patients will be enrolled and treated in the US. The follow-up duration for this&#xD;
      post-approval study will be 36-months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)</measure>
    <time_frame>36 months</time_frame>
    <description>Estimate the 36-month freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ Cardiac Cryoablation Catheter System.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Primary Safety Events</measure>
    <time_frame>12 months</time_frame>
    <description>Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ Cardiac Cryoablation Catheter System through 12-months.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arctic Front™ Cardiac Cryoablation Catheter System</intervention_name>
    <description>Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a&#xD;
        recommendation for a pulmonary vein ablation with the Arctic Front™ Cardiac Cryoablation&#xD;
        Catheter System may be approached regarding enrollment in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has been diagnosed with persistent AF.&#xD;
&#xD;
          -  Subject is ≥ 18 years of age or minimum age as required by local regulations.&#xD;
&#xD;
          -  Planned pulmonary vein isolation (PVI) procedure using commercially available Arctic&#xD;
             Front™ Cardiac Cryoablation Catheter System.&#xD;
&#xD;
          -  Willing to comply with study requirements and give informed consent (defined as&#xD;
             legally effective, documented confirmation of a subject's voluntary agreement to&#xD;
             participate in this clinical study) or authorization per institution and geographical&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI)&#xD;
             ablation for AFL).&#xD;
&#xD;
          -  Subject is enrolled in a concurrent study that has not been approved for concurrent&#xD;
             enrollment by the global study manager.&#xD;
&#xD;
          -  Subject with exclusion criteria required by local law.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brien Neudeck, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Clinical Research Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Troy Penz</last_name>
    <phone>763-337-2477</phone>
    <email>troy.d.penz@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Sauline</last_name>
    <email>mary.k.sauline@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801-2500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Rhee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525-6427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Gauri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Beyerbach, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-1852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tschopp, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Health Research &amp; Education Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Lampe, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

